TAHO Pharma
泰合生技藥品股份有限公司
TAHO Pharma is a Taiwan TWSE-listed biotechnology company; its most advanced asset is TAH4411 (Marketing authorization obtained; marketed, Chemotherapy-induced nausea and vomiting), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| TAH4411 | — | Marketing authorization obtained; marketed | Chemotherapy-induced nausea and vomiting | Japan | 2026-09-05 | Company disclosure |
| TAH3311 | — | NDA in standard review | Antithrombotic therapy | United States | 2026-09-05 | Company disclosure |
Key events
- TAH3311: NDA in standard review; TAH4411: Marketing authorization obtained; marketed
Related Drugnews articles
No related articles in this language.